MS CATHERINE J. BAKER (Orcid ID : 0000-0001-5299-1465) DR STEPHANIE ANN SMITH (Orcid ID : 0000-0003-4895-6215) DR JAMES H MORRISSEY (Orcid ID : 0000-0002-1570-1569)

Article type : Illustrated Review

# Polyphosphate in Thrombosis, Hemostasis and Inflammation

# Catherine J. Baker MS, Stephanie A. Smith DVM, and James H. Morrissey PhD

Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan,

USA

# Correspondence to:

James H. Morrissey

Email: (jhmorris@umich.edu)

Mailing address:

Department of Biological Chemistry University of Michigan Medical School

4301B MSRB III

1150 West Medical Center Dr.

Ann Arbor, MI, USA 48109-5606

Twitter handle: @JHMorrissey

Phone: 1+734-763-3989

Running Title: Polyphosphate in Thrombosis, Hemostasis and Inflammation

Article type: Illustrated Review

**Key Words:** Polyphosphate; Nucleic acids; Contact pathway; Blood coagulation; DNA; RNA This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the <u>Version of Record</u>. Please cite this article as <u>doi:</u> <u>10.1002/rth2.12162</u>

This article is protected by copyright. All rights reserved

#### Essentials

- Polyphosphate is present in microorganisms and human cells such as platelets
- Polyphosphate modulates coagulation via interactions with multiple proteins
- Polyphosphate modulates inflammation by triggering bradykinin release and inhibiting complement
- Nucleic acids and polyphosphate co-purify and may be contaminated with silica-based methods

# Abstract

This illustrated review focuses on polyphosphate as a potent modulator of the plasma clotting cascade, with possible roles in hemostasis, thrombosis and inflammation. Polyphosphates are highly anionic, linear polymers of inorganic phosphates that are widespread throughout biology. Infectious microorganisms accumulate polyphosphates with widely varying polymer lengths (from a few phosphates to over a thousand phosphates long), while activated human platelets secrete polyphosphate with a very narrow size distribution (about 60-100 phosphates long). Work from our lab and others has shown that long-chain polyphosphate is a potent trigger of clotting via the contact pathway, while polyphosphate of the size secreted by platelets accelerates factor V activation, blocks the anticoagulant activity of tissue factor pathway inhibitor, promotes factor XI activation by thrombin, and makes fibrin fibrils thicker and more resistant to fibrinolysis. Polyphosphate also modulates inflammation by triggering bradykinin release, inhibiting the complement system, and modulating endothelial function. Polyphosphate and nucleic acids have similar physical properties and both will trigger the contact pathway-although polyphosphate is orders of magnitude more procoagulant than either DNA or RNA. Important caveats in these studies include observations that nucleic acids and polyphosphate may co-purify, and that these preparations can be contaminated with highly procoagulant microparticles if silica-based purification methods are employed. Polyphosphate has received attention as a possible therapeutic, with some recent studies exploring the use of polyphosphate in a variety of formulations to control bleeding. Other studies are investigating treatments that block polyphosphate function as novel antithrombotics with the possibility of reduced bleeding side effects.

## Acknowledgements

The authors thank Roberto Docampo for sharing his platelet images.

## Disclosures

SAS and JHM hold patents related to the potential medical uses of polyphosphate and polyphosphate inhibitors. JHM has equity ownership in PrevThro Pharmaceuticals and consults for Cayuga Pharmaceuticals.

# **Authorship Details**

**.** 

CJB created the graphics; SAS contributed images and wrote the text; CJB, SAS, and JHM contributed to the conceptual design and edited the manuscript.

## References

1 Rao NN, Gómez-García MR, Kornberg A. Inorganic polyphosphate: essential for growth and survival. *Annu Rev Biochem*. 2009; **78**: 605-47. 10.1146/annurev.biochem.77.083007.093039.

2 Ruiz FA, Rodrigues CO, Docampo R. Rapid changes in polyphosphate content within acidocalcisomes in response to cell growth, differentiation, and environmental stress in *Trypanosoma cruzi*. *J Biol Chem*. 2001; **276**: 26114-21. 10.1074/jbc.M102402200.

3 Docampo R, Moreno SN. Acidocalcisomes. *Cell Calcium*. 2011; **50**: 113-9.
10.1016/j.ceca.2011.05.012.

4 Ruiz FA, Lea CR, Oldfield E, Docampo R. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. *J Biol Chem.* 2004; **279**: 44250-7.

5 Moreno-Sanchez D, Hernandez-Ruiz L, Ruiz FA, Docampo R. Polyphosphate is a novel proinflammatory regulator of mast cells and is located in acidocalcisomes. *J Biol Chem*. 2012; **287**: 28435-44. 10.1074/jbc.M112.385823.

6 Nickel KF, Ronquist G, Langer F, Labberton L, Fuchs TA, Bokemeyer C, Sauter G, Graefen M, Mackman N, Stavrou EX, Ronquist G, Renné T. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. *Blood.* 2015; **126**: 1379-89. 10.1182/blood-2015-01-622811.

Dedkova EN. Inorganic polyphosphate in cardiac myocytes: from bioenergetics to the permeability transition pore and cell survival. *Biochem Soc Trans*. 2016; 44: 25-34.
10.1042/BST20150218.

8 Seidlmayer LK, Gómez-García MR, Blatter LA, Pavlov E, Dedkova EN. Inorganic polyphosphate is a potent activator of the mitochondrial permeability transition pore in cardiac myocytes. *J Gen Physiol.* 2012; **139**: 321-31. 10.1085/jgp.201210788.

9 Kumble KD, Kornberg A. Inorganic polyphosphate in mammalian cells and tissues. *J Biol Chem*. 1995; **270**: 5818-22.

10 Stotz SC, Scott LO, Drummond-Main C, Avchalumov Y, Girotto F, Davidsen J, Gómez-García MR, Rho JM, Pavlov EV, Colicos MA. Inorganic polyphosphate regulates neuronal excitability through modulation of voltage-gated channels. *Mol Brain*. 2014; **7**: 42. 10.1186/1756-6606-7-42.

11 Noegel A, Gotschlich EC. Isolation of a high molecular weight polyphosphate from *Neisseria gonorrhoeae*. *J Exp Med*. 1983; **157**: 2049-60.

Zhang Q, Li Y, Tang CM. The role of the exopolyphosphatase PPX in avoidance by *Neisseria meningitidis* of complement-mediated killing. *J Biol Chem.* 2010; **285**: 34259-68.
 10.1074/jbc.M110.154393.

13 Tinsley CR, Gotschlich EC. Cloning and characterization of the meningococcal polyphosphate kinase gene: production of polyphosphate synthesis mutants. *Infect Immun.* 1995; **63**: 1624-30.

Smith SA, Choi SH, Davis-Harrison R, Huyck J, Boettcher J, Rienstra CM, Morrissey JH.
 Polyphosphate exerts differential effects on blood clotting, depending on polymer size. *Blood*. 2010; **116**: 4353-9. 10.1182/blood-2010-01-266791.

15 Engel R, Brain CM, Paget J, Lionikiene AS, Mutch NJ. Single-chain factor XII exhibits activity when complexed to polyphosphate. *J Thromb Haemost*. 2014; **12**: 1513-22. 10.1111/jth.12663.

Müller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, Schmidbauer S, Gahl WA,
 Morrissey JH, Renné T. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo.
 *Cell*. 2009; 139: 1143-56. 10.1016/j.cell.2009.11.001.

Seligsohn U. Factor XI deficiency in humans. *J Thromb Haemost*. 2009; **7 Suppl 1**: 84-7.
10.1111/j.1538-7836.2009.03395.x.

Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII.
 Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. *J Biol Chem.* 1991; 266: 7353-8.

19 Gailani D, Broze GJ, Jr. Factor XI activation in a revised model of blood coagulation. *Science*.1991; 253: 909-12.

20 Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. *Blood*. 2011; **118**: 6963-70. 10.1182/blood-2011-07-368811.

Geng Y, Verhamme IM, Smith SB, Sun M-f, Matafonov A, Cheng Q, Smith SA, Morrissey JH,
Gailani D. The dimeric structure of factor XI and zymogen activation. *Blood*. 2013; **121**: 3962-9.
10.1182/blood-2012-12-473629.

Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates
 blood coagulation and fibrinolysis. *Proc Natl Acad Sci U S A*. 2006; **103**: 903-8.
 10.1073/pnas.0507195103.

Ivanov I, Shakhawat R, Sun MF, Dickeson SK, Puy C, McCarty OJ, Gruber A, Matafonov A, Gailani D. Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kininogen. *Thromb Haemost*. 2017; **117**: 671-81. 10.1160/TH16-09-0691.

24 Choi SH, Smith SA, Morrissey JH. Polyphosphate accelerates factor V activation by factor XIa. *Thromb Haemost.* 2015; **113**: 599-604. 10.1160/th14-06-0515.

Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. *Blood*. 2008; **112**: 2810-6.
10.1182/blood-2008-03-145755.

Mutch NJ, Engel R, Uitte de Willige S, Philippou H, Ariens RA. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. *Blood.* 2010; **115**: 3980-8. 10.1182/blood-2009-11-254029.

Wijeyewickrema LC, Lameignere E, Hor L, Duncan RC, Shiba T, Travers RJ, Kapopara PR, Lei V, Smith SA, Kim H, Morrissey JH, Pike RN, Conway EM. Polyphosphate is a novel cofactor for regulation of complement by a serpin, C1 inhibitor. *Blood.* 2016; **128**: 1766-76. 10.1182/blood-2016-02-699561.

Wat JM, Foley JH, Krisinger MJ, Ocariza LM, Lei V, Wasney GA, Lameignere E, Strynadka NC, Smith SA, Morrissey JH, Conway EM. Polyphosphate suppresses complement via the terminal pathway. *Blood*. 2014; **123**: 768-76. 10.1182/blood-2013-07-515726.

Hassanian SM, Dinarvand P, Smith SA, Rezaie AR. Inorganic polyphosphate elicits proinflammatory responses through activation of mTOR complexes 1 and 2 in vascular endothelial cells. *J Thromb Haemost*. 2015. 10.1111/jth.12899.

30 Dinarvand P, Hassanian SM, Qureshi SH, Manithody C, Eissenberg JC, Yang L, Rezaie AR. Polyphosphate amplifies proinflammatory responses of nuclear proteins through interaction with receptor for advanced glycation end products and P2Y<sub>1</sub> purinergic receptor. *Blood*. 2014; **123**: 935-45. 10.1182/blood-2013-09-529602.

31 Smith SA, Gajsiewicz JM, Morrissey JH. Ability of polyphosphate and nucleic acids to trigger blood clotting: Some observations and caveats. *Front Med.* 2018; **5**: 107. 10.3389/fmed.2018.00107.

32 Smith SA, Baker CJ, Gajsiewicz JM, Morrissey JH. Silica particles contribute to the procoagulant activity of DNA and polyphosphate isolated using commercial kits. *Blood.* 2017; **130**: 88-91. 10.1182/blood-2017-03-772848.

33 Branzk N, Papayannopoulos V. Molecular mechanisms regulating NETosis in infection and disease. *Semin Immunopathol.* 2013; **35**: 513-30. 10.1007/s00281-013-0384-6.

Martinod K, Wagner DD. Thrombosis: tangled up in NETs. *Blood*. 2014; **123**: 2768-76.
10.1182/blood-2013-10-463646.

35 Esmon CT. Molecular circuits in thrombosis and inflammation. *Thromb Haemost.* 2013; **109**: 416-20. 10.1160/TH12-08-0634.

Kudela D, Smith SA, May-Masnou A, Braun GB, Pallaoro A, Nguyen CK, Chuong TT, Nownes
 S, Allen R, Parker NR, Rashidi HH, Morrissey JH, Stucky GD. Clotting activity of polyphosphate functionalized silica nanoparticles. *Angew Chem Int Ed.* 2015; 54: 4018-22. 10.1002/anie.201409639.

37 Yeon JH, Mazinani N, Schlappi TS, Chan KYT, Baylis JR, Smith SA, Donovan AJ, Kudela D, Stucky GD, Liu Y, Morrissey JH, Kastrup CJ. Localization of short-chain polyphosphate enhances its ability to clot flowing blood plasma. *Sci Rep.* 2017; **7**: 42119. 10.1038/srep42119.

Donovan AJ, Kalkowski J, Smith SA, Morrissey JH, Liu Y. Size-controlled synthesis of granular polyphosphate nanoparticles at physiologic salt concentrations for blood clotting. *Biomacromolecules*.
 2014. 10.1021/bm501046t.

39 Szymusiak M, Donovan AJ, Smith SA, Ransom R, Shen H, Kalkowski J, Morrissey JH, Liu Y. Colloidal confinement of polyphosphate on gold nanoparticles robustly activates the contact pathway of blood coagulation. *Bioconj Chem.* 2016; **27**: 102-9. 10.1021/acs.bioconjchem.5b00524.

40 Schröder HC, Tolba E, Diehl-Seifert B, Wang X, Müller WE. Electrospinning of bioactive wound-healing nets. *Prog Mol Subcell Biol*. 2017; **55**: 259-90. 10.1007/978-3-319-51284-6\_8.

41 Donovan AJ, Kalkowski J, Szymusiak M, Wang C, Smith SA, Klie RF, Morrissey JH, Liu Y. Artificial dense granules: A procoagulant liposomal formulation modeled after platelet polyphosphate storage pools. *Biomacromolecules*. 2016; **17**: 2572-81. 10.1021/acs.biomac.6b00577.

42 Sakoda M, Kaneko M, Ohta S, Qi P, Ichimura S, Yatomi Y, Ito T. Injectable hemostat composed of a polyphosphate-conjugated hyaluronan hydrogel. *Biomacromolecules*. 2018; **19**: 3280-90. 10.1021/acs.biomac.8b00588.

Wang Y, Kim K, Lee MS, Lee H. Hemostatic ability of chitosan-phosphate inspired by coagulation mechanisms of platelet polyphosphates. *Macromol Biosci*. 2018; **18**: e1700378. 10.1002/mabi.201700378.

Ong SY, Wu J, Moochhala SM, Tan MH, Lu J. Development of a chitosan-based wound dressing with improved hemostatic and antimicrobial properties. *Biomaterials*. 2008; **29**: 4323-32.
10.1016/j.biomaterials.2008.07.034.

Zhu S, Travers RJ, Morrissey JH, Diamond SL. FXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen/tissue factor surfaces under flow. *Blood*. 2015; 126: 1494-502. 10.1182/blood-2015-04-641472.

Travers RJ, Shenoi RA, Kalathottukaren MT, Kizhakkedathu JN, Morrissey JH. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. *Blood*. 2014; **124**: 3183-90. 10.1182/blood-2014-05-577932.

47 Smith SA, Morrissey JH. Polyphosphate as a general procoagulant agent. *J Thromb Haemost*.
2008; 6: 1750-6. 10.1111/j.1538-7836.2008.03104.x.

Smith SA, Choi SH, Collins JN, Travers RJ, Cooley BC, Morrissey JH. Inhibition of
polyphosphate as a novel strategy for preventing thrombosis and inflammation. *Blood*. 2012; **120**: 510310. 10.1182/blood-2012-07-444935.

49 Wurst H, Kornberg A. A soluble exopolyphosphatase of *Saccharomyces cerevisiae*. Purification and characterization. *J Biol Chem.* 1994; **269**: 10996-1001.

50 Lorenz B, Schröder HC. Mammalian intestinal alkaline phosphatase acts as highly active exopolyphosphatase. *Biochim Biophys Acta*. 2001; **1547**: 254-61.

51 Labberton L, Kenne E, Long AT, Nickel KF, Di Gennaro A, Rigg RA, Hernandez JS, Butler L, Maas C, Stavrou EX, Renné T. Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection. *Nat Commun.* 2016; **7**: 12616. 10.1038/ncomms12616.

Jain S, Pitoc GA, Holl EK, Zhang Y, Borst L, Leong KW, Lee J, Sullenger BA. Nucleic acid scavengers inhibit thrombosis without increasing bleeding. *Proc Natl Acad Sci U S A*. 2012; **109**: 12938-43. 10.1073/pnas.1204928109.

Author Ma